Unibest

Pharmaceutical intermediates

Enasidenib Mesylate Intermediates

4 pharmaceutical intermediates for Enasidenib Mesylate. Indication: Leukemia, Myeloid, Acute.

提交项目All intermediates

About Enasidenib Mesylate

Originator
Celgene Corporation; Agios Pharmaceuticals Inc; Laboratoires Servier
Indication
Leukemia, Myeloid, Acute
Approved Date
08/01/2017
DS/DP
06/21/2030

Available intermediates

4 intermediates currently listed for Enasidenib Mesylate. Request specifications, documentation or a quotation for any item below.

Enasidenib Mesylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Amino-2-trifluoromethylpyridine147149-98-2 //
2-Trifluoromethyl-6-pyridinecarboxylic acid131747-42-7//
6-Trifluoromethyl-pyridine-2-carboxylic acid methyl ester155377-05-2//
6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione1446507-38-5//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Enasidenib Mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →